| Literature DB >> 32919760 |
John W Frew1, Angelo V Marzano2, Kerstin Wolk3, Olivier Join-Lambert4, Afsaneh Alavi5, Michelle A Lowes6, Vincent Piguet5.
Abstract
This systematic review identifies and critically evaluates the mechanistic and clinical evidence of new promising therapeutic targets in hidradenitis suppurativa (HS). Evidence for these targets is largely based on observational data with limited ex vivo and translational data from clinical trials. A number of placebo-controlled studies have been completed or are underway utilizing IL-1, IL-23, IL-17, complement, and Jak inhibition, although there is concern regarding elevated placebo response rates and the questionable validity of clinical scores in some participant subsets. Knowledge gaps are identified suggesting a direction for future mechanistic studies in HS, including more comprehensive inflammatory endotype profiling of disease.Entities:
Year: 2020 PMID: 32919760 DOI: 10.1016/j.jid.2020.06.019
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551